Changing Paradigms in the Diagnosis and Treatment of Multiple Myeloma

Saturday, February 25, 2017
7:00 AM - 3:15 PM

Program Director
Robert Orlowski, MD, PhD
Professor of Medicine,
Department of Lymphoma/Myeloma,
Division of Cancer Medicine,
The University of Texas MD Anderson Cancer Center,
Houston, TX

Educational Grants
This activity is supported by education grants from:
Amgen, Inc.

Jointly provided by

For online registration and more information visit: www.cancernetus.com

REGISTRATION FORM
Changing Paradigms in the Diagnosis and Treatment of Multiple Myeloma

First Name ___________________________ Middle Initial ________ Last Name ___________________________

☐ Physician  ☐ Pa-C  ☐ NP  ☐ PhD  ☐ Pharmacist  ☐ Industry  ☐ Nurse  ☐ Other

Mailing Address ____________________________

City ___________________________ State _____ Zip Code ______

Phone ___________________________ Fax ___________________________

E-Mail ___________________________

Speciality ___________________________

Registration Fee (Registration fee partially covers buffet breakfast, lunch and syllabus book)

Early Registration Fee - Up to 1/31/17 $100.00
Discounted Registration Fee - 2/1/17 - 2/15/17 $130.00
Regular Registration Fee - 2/16/17 - 2/25/17 $160.00

☐ Physicians
☐ Nurses, Nurse Practitioners, Physician Assistants
☐ Pharmacists, Fellows
☐ Industry ♠

$75.00 $95.00 $115.00
$75.00 $95.00 $115.00
$350.00 $400.00 $450.00

십시오 Person(s) employed by for-profit organizations such as pharmaceutical and biotech companies, and financial institutions

No refund. Substitution is allowed.

Payment may be made: ☐ MC  ☐ Visa  ☐ Discover  ☐ Check

Credit Card Number _______________ Expiration Date _______________

Name and address (as given on the monthly credit card statement) ___________________________

Pharmacists only: NABP e-profile # _______________ Birth Date (MMDD): _______________

Signature ___________________________

Register online at www.cancernetus.com

To reserve your place for the meeting, please complete the registration form and fax it to 443-267-0016. For questions, please call Brian Waggoner at 972-459-5222 or E-mail: brianw@cancernetus.com

Houston Marriott at the Texas Medical Center
6580 Fannin St, Houston, TX 77030
Phone: (713) 796-0080

Please make checks payable to CancerNet. Mail checks to CancerNet, 860 Hebron Pkwy, Suite 1104, Lewisville, TX 75057

To reserve your space for the meeting, please complete the registration form and fax it to 443-267-0016. For questions, please call Brian Waggoner at 972-459-5222 or E-mail: brianw@cancernetus.com
Changing Paradigms in the Diagnosis and Treatment of Multiple Myeloma

Saturday, February 25, 2017
Houston Marriott at the Texas Medical Center
6580 Fannin St, Houston, TX 77030
Phone: (713) 796-0080

Statement of Need / Program Overview

This symposium is intended to improve care of patients with multiple myeloma by accelerating adoption of new guidelines and evidence-based practice change. The format will include didactic lectures from known opinion leaders, question and answer sessions, and ample opportunity for participant interaction with faculty.

Target Audience

This symposium is directed primarily to hematologists/oncologists, radiation oncologists, researchers, pharmacists, registered nurses, physician assistants, nurse practitioners and fellows in training interested in new development in multiple myeloma (MM). No specific skill or knowledge other than a basic training in hematology/oncology is required for successful participation in this activity.

Learning Objectives

After completing this activity, the participant should be better able to:

• Describe the multiple myeloma (MM) disease definitions and diagnostic criteria based on IMWG guidelines
• Outline the classification and risk stratification on MM and smoldering MM
• Identify and select ASCT and/or AST in transplantation eligible patients with newly diagnosed MM
• Identify benefit and risks of available immunomodulatory agents, proteasome inhibitors or both as systemic therapy for patients with newly diagnosed active MM
• Customize the use of maintenance therapy approaches in the post-transplant and non-transplant settings based on patient- and disease related factors including cytogenetic profile
• Evaluate available data on the selection, sequencing and/or combination of novel therapeutic agents in the treatment of patients with relapsed/refractory MM
• Describe the natural history of precursor disorder, either smoldering myeloma or MGUS and see whether disease state can be altered by treating earlier to avoid progression to MM
• Assess the ongoing clinical trials investigating the innovative approaches for MM and refer patients for study participation.
### Agenda

**Changing Paradigms in the Diagnosis and Treatment of Multiple Myeloma**

**7:00 AM** Registration and Breakfast

**8:25 AM** Introduction and Opening Remarks | Robert Orlowski, MD, PhD

**8:30 AM** State of the Art in Biology, Therapy and Patient Care of Multiple Myeloma (MM): A 2016 Update | Robert Orlowski, MD, PhD

**9:00 AM** Update on MM Disease Definitions and Diagnostic Criteria Based on IMWG Guidelines | Gareth Morgan, MD, PhD

**9:30 AM** Update on Classification and Risk Stratification on MM and Smoldering MM | TBD

**10:00 AM** Panel Discussion and Case Presentation | Robert Orlowski, MD, PhD / Gareth Morgan, MD, PhD / TBD

**10:15 AM** BREAK

**10:30 AM** Update on ASCT and AST in Transplantation-Eligible Patients With Newly Diagnosed MM | Jatin Shah, MD

**11:00 AM** An Overview on Systemic Therapy for Patients with Newly Diagnosed Active MM | Elizabet Manasanch, MD

**11:30 AM** Outline the Selection, Sequencing and/or Combination of Novel Therapies for Patients with Relapsed/refractory MM | Gareth Morgan, MD, PhD

**12:00 PM** Panel Discussion and Case Presentation | Jatin Shah, MD / Elizabet Manasanch, MD / Gareth Morgan, MD, PhD

**12:15 PM** LUNCH

**1:15 PM** Describe the Smoldering Myeloma or MGUS and Whether Disease State can be Altered by Treating Earlier to Avoid Progression to MM | TBD

**1:45 PM** Maintenance Therapy Approaches in the Post-transplant and Non-transplant Settings Based on Patient- and Disease Related Factors Including Cytogenetic Profile | Michael Wang, MD

**2:15 PM** BREAK

**2:30 PM** New Drugs and Clinical Trials Investigating the Innovative Approaches for MM: Refer Patients for Study Participation | Robert Orlowski, MD, PhD

**3:00 PM** Panel Discussion and Case Presentation | TBD / Michael Wang, MD / Robert Orlowski, MD, PhD

**3:15 PM** Closing Remarks and Adjourn | Robert Orlowski, MD, PhD

---

**Physician Continuing Education**

**Accreditation Statement:**
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health and CancerNet. The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health is accredited by the ACCME to provide continuing medical education for physicians.

**Credit Designation:**
This activity provides 5.25 contact hours (0.525 CEUs) - Application based credits
ACPE Universal Activity Number: 0280-9999-16-073-L01-P

**Participant Requirements (Nurses and Pharmacists) for Credit:**
- Participants must fully attend all sessions as well as pass in a completed signature verification form (No partial credit will be given).
- Participants can earn Continuing Education credits for this program by electronically logging onto the website https://ce.ahrevents.com/ and completing the session evaluation form for sessions attended.
- Nurses: After completion of the evaluation, certificate of credit can be printed.
- Pharmacists: After completion of the activity evaluation, pharmacy education credit is automatically reported to CPE Monitor where a certificate of credit can be printed. Please allow up to 48 hours for credit to be available on the CPE Monitor.

*Only Certificates of Credit issued from CPE Monitor are valid in the US*
- CPE Monitor will not accept credits after 60 days from the session date
- All participant names will be checked against program attendance sheets for verification of attendance.

**Disclosure & Evaluation:**
All participants will have the opportunity to evaluate the educational session and presenter as well as the ability to identify their future educational needs. Disclosure will be made on the day of the program regarding any interest or affiliation a speaker may have with a supporting organization.

---

**Nursing Continuing Education**

**Accreditation Statement:**
American Health Resources, Inc. is approved by the California Board of Registered Nursing, Provider # CEP 14254 and approved this program for 5.25 contact hours. Please check with licensing board to verify credits can be claimed in your state.

**Pharmacist Continuing Education**

**Accreditation Statement:**
American Health Resource is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

---

**Participants may reserve guest rooms by calling (713) 796-0080**

860 Hebron Pkwy, Suite 1104, Lewisville, TX 75057
Tel: (972) 459-5222 • Fax: (443) 267-0016
www.cancernetus.com